Introduction
Fibroblast growth factor-2 (FGF-2 or bFGF, basic Fibroblast Growth Factor) is the prototype member of an ever-increasing gene family of growth factors which comprises to date 23 factors involved in the control of cell proliferation and dierentiation (Nishimura et al., 1999; Yamashita et al., 2000) . FGF-2 has been shown to stimulate endothelial cell growth and migration in vitro as well as in vivo angiogenesis and has long been considered as the principal tumour angiogenic factor (Kandel et al., 1991) . FGF-2 is also implicated in wound-healing processes and has a potential oncogenic eect (for review, see Bikfalvi et al., 1997) . The multiple roles carried out by FGF-2 require a strong and subtle control of its synthesis. Although numerous studies have described transcriptional regulations of FGF-2 expression, such regulations cannot account for the dierential expression of FGF-2 which is synthesized as ®ve molecular forms with dierent localization and functions (Arnaud et al., 1999; Bikfalvi et al., 1997; Florkiewicz and Sommer, 1989; Prats et al., 1989) . Expression of the FGF-2 isoforms is translationally regulated by stress and cell density in normal human cells, whereas these isoforms are constitutively expressed in transformed cells (Galy et al., 1999; Vagner et al., 1996) . Several cis-acting elements located within the FGF-2 mRNA leader sequence are involved in the control of FGF-2 translation (Prats et al., 1992) . In particular, an internal ribosome entry site (IRES) allows FGF-2 mRNA translation to occur via a non classical capindependent mechanism (Vagner et al., 1995) . This IRES is constitutively active in transformed cells and could account for abnormal expression of FGF-2 isoforms (Galy et al., 1999) .
The deregulation of FGF-2 isoform expression at the translational level observed in a wide range of cancerous strains suggested the involvement of a tumour suppressor in the control of FGF-2 mRNA translation. A few data suggest that tumour suppressor p53, although mostly described as a transcriptional modulator, also participates in post-transcriptional control processes (Ewen and Miller, 1996) . It is, for instance, required for the translational repression of cdk4 expression in G1 arrested cells treated with transforming growth factor b1 (TGFb1) (Ewen et al., 1995; Miller et al., 2000) . In vitro, murine p53 is also able to bind to the 5' leader region and to repress the translation of its own messenger RNA (Mosner et al., 1995) .
Here we report that the FGF-2 mRNA translation in primary human skin ®broblasts at low cell density, is inversely correlated with p53 expression. We show that p53 is able to repress FGF-2 expression by a posttranscriptional mechanism involving the FGF-2 mRNA leader sequence. The use of a set of p53 mutants, p73a or p21/waf as eectors led us to conclude that the posttranscriptional inhibition of FGF-2 expression by p53 occurs through a mechanism independent of its transcriptional trans-activating activity.
Results

FGF-2 mRNA translation in human skin fibroblasts is inversely correlated with p53 expression
We have previously shown a strong discrepancy between FGF-2 mRNA and protein levels in human skin ®broblasts at low cell densities (Galy et al., 1999) . Here we analysed the eciency of translation of the FGF-2 mRNA in parallel with p53 protein expression in human skin ®broblasts, as a function of cell density (Figure 1 ). FGF-2 mRNA was quanti®ed by quantitative reverse transcription and polymerase chain reaction (RT ± PCR) (Figure 1a ), whereas protein expression was revealed by Western immunoblotting (Figure 1b) . The ratio of amounts of FGF-2 proteins to mRNA showed that the FGF-2 mRNA was translated with a 10-fold lower eciency, whereas p53 expression showed a considerable increase, in low density compared to high density cells (Figure 1c, compare lanes 1 and 3) . As expected, expression of the p53 transcriptional target p21 also increased, while the control b-actin was unaected by cell density. These data suggest a direct correlation between the increase in FGF-2 mRNA translation eciency and a decrease in p53 expression.
Wild-type p53 post-transcriptionally inhibits FGF-2 expression
In order to study the post-transcriptional eects of p53 on human FGF-2 expression, human p53 was coexpressed with a chimeric FGF ± CAT RNA in Figure 1 Eect of cell density on FGF-2 mRNA translation and p53 expression in normal primary human skin ®broblasts. Normal primary human skin ®broblasts (HuNSF) were seeded at dierent densities (35, 140 and 420 cells/mm 2 ) and harvested 72 h later for analysis of mRNA expression and FGF-2 protein. (a) mRNA levels were determined by quantitative RT ± PCR as described in Materials and methods. (b) Protein levels were obtained by Western immunoblotting as described previously (Galy et al., 1999) . Histograms represent quanti®cation of the FGF-2 isoforms from the Western blot using ImageQuant software. This corresponds to a representative experiment that was repeated at least 10 times. (c) The total amount of FGF-2 isoforms was calibrated against the messenger level to evaluate the translatability of the FGF-2 mRNA. The levels of p53 and p21 were studied in parallel by Western blot with the DO-1 monoclonal anti-p53 and the SC-127 polyclonal anti-p21 antibodies (Santa-Cruz Inc.). The control is given by the level of b-actin determined as previously described (Galy et al., 1999) transiently transfected cells. This RNA allows the expression of all FGF ± CAT isoforms which can then easily be distinguished from endogenous FGF-2 by using an anti-CAT antibody (Vagner et al., 1996) . Coexpression was obtained by using a single bigenic plasmid bearing both the p53 (eector) and the FGF ± CAT (target) genes under the control of two identical CMV promoters (Figure 2a ). In this way both genes were always co-expressed in the same cell, thus representing an advantage over a co-transfection procedure. We used a wild-type (wt p53) or a well characterized mutant form of p53 (Ala 143 ), in which valine 143 had been substituted by an alanine (Baker et al., 1990) , and a mutated form of the hormone binding domain of the human oestrogen receptor (Kumar et al., 1986) as control eectors. As control targets, we used an FGF ± CAT RNA deleted of most of the FGF-2 mRNA leader but that still retained the AUG initiation codon, and CAT RNA alone (Figure 2a) . We also used an FGF ± CAT target RNA in which the CAT ORF was fused at the carboxy-terminal end of the FGF-2 ORF.
SK-Hep-1 cells were transfected with the dierent plasmids and then harvested 48 h later for Western blot and RNase protection analysis. Figure 2b shows the detection of FGF ± CAT and p53 proteins expression. Little endogenous p53 could be detected in mock transfected cells ( Figure 2b ). As expected, all the Figure 2 Inhibitory eect of wt p53 on the post-transcriptional expression of an FGF ± CAT chimeric construct. (a) Representation of the bigenic vectors used to co-express wt p53, Ala 143 p53 or the control protein (a mutated form of the hormone binding domain of the human oestrogen receptor (Kumar et al., 1986) ) as eectors together with the target RNA consisting of a fusion of the ®rst 539 nt of the FGF-2 mRNA leader with CAT ± ORF (FC). The other target RNAs used were FC deleted for the ®rst 466 nt (D1 ± 466), CAT ± ORF alone (C) or CAT fused at the Cterm end to the FGF-2 ORF (FC*). The aim of the study was to determine the eect of the eector protein on the expression of FGF ± CAT chimeric proteins. The positions of the FGF-2 mRNA start codons are shown (C1, C2, C3 and A for FC and D1 ± 466 and C1*, C2*, C3* and A* for FC* corresponding to CUG1, CUG2, CUG3 and AUG start codons, respectively). (b) SK-Hep-1 cells were transfected with bigenic vectors and harvested 48 h later for Western blot analysis of FGF ± CAT protein expression (upper panel) as described in Materials and methods. Expression of p53 was checked by using the monoclonal anti-p53 antibody DO-1 (lower panel). The FGF ± CAT proteins initiated at the CUG2 and CUG3 codons migrated as a single band. The positions of the signals corresponding to the dierent FGF ± CAT isoforms (C1, C2/3 and A for FC and C1*, C2/3* and A* for FC*) and to CAT and p53 proteins are indicated by arrows. The eector proteins and target RNAs encoded by the dierent bigenic vectors used to transfect cells are indicated above each lane (lanes 1 ± 9). (c) Total RNAs were extracted from cells transfected in (b) (lanes 1 ± 9) and the levels of CAT ± ORF containing RNAs were determined by RNase protection assay as described in Materials and methods. The signals corresponding to CAT and CAT chimeric proteins in (b) were quanti®ed by using a laser densitometer (Molecular Dynamics) and the Image Quant software (at least two exposure times were used for quanti®ca-tion). Histograms represent the protein levels calibrated against RNA levels for each transfection assay. The results presented here and in all the other ®gures are representative of at least four independent experiments. To rule out a possible eect of p53 on the CMV promoter function, the FGF ± CAT protein expression was calibrated to the FGF ± CAT mRNA level determined by RNase protection assay (Figure 2c ). We concluded that wt p53 could produce an approximately 15-fold repression of FGF ± CAT expression at a post-transcriptional level (Figure 2c , lower histogram lanes 2 and 3). It should be noted that wt p53 repressed the expression of all FGF ± CAT proteins without producing any variation in the relative amounts of the dierent isoforms. Addition of the entire FGF-2 ORF (Figure 2a , FC*) gave similar results to the previous FGF ± CAT fusion indicating that the ORF part of the messenger was not involved in the p53 mediated downregulation of FGF ± CAT isoforms expression ( Figure  2b and c, compare lanes 2 and 3 with lanes 8 and 9).
It is of interest that when most of the FGF-2 RNA leader was deleted so that only the AUG initiated FGF ± CAT protein was synthesized, or when we used CAT RNA alone, the inhibitory eect of wt p53 was no longer observed ( Figure 2b and c, lanes 4 and 5 and lanes 6 and 7, respectively). These results show that: (i) wt p53 does not inhibit general post-transcriptional expression; and (ii) the inhibitory eect of wt p53 on FGF ± CAT expression is not the result of increased degradation of chimeric proteins since AUG ± CAT expression is unaected. We therefore concluded that the FGF-2 RNA leader mediates a repressor eect of wt p53 on FGF-2 expression through a post-transcriptional mechanism.
The repressor eect of p53 obtained in SK-Hep-1 cells, a cell lineage of endothelial origin, was observed in various transformed human cells of dierent histologic origins including Hela cells (cervix epithelial cells), MDAH cells (®broblasts from patients with Li ± Fraumeni syndrome) and Saos-2 osteosarcoma cells (Figure 2d and data not shown). This suggests that the post-transcriptional inhibitory eect of wt p53 on FGF-2 expression is independent of cell-type speci®c factors.
VEGF and PDGF mRNA leader sequences do not mediate the p53 inhibitory effect
To determine whether the wt p53 eect was speci®c to FGF-2 mRNA or not, we then fused the 5' leader regions of the human vascular endothelial growth factor A (VEGF-A) and of the human platelet derived growth factor (PDGF) to the CAT ORF in the bigenic vectors. These RNA leaders share common features with those of FGF-2: (i) they are very long (1038 nt and 1022 nt, respectively); (ii) they are G-C rich and thus highly structured; and (iii) they contain IRESes (Bernstein et al., 1997; Huez et al., 1998; Kumar et al., 1986; Stein et al., 1998) .
SK-Hep-1 cells were transiently transfected with the bigenic plasmids encoding VEGF ± CAT or PDGF ± CAT fusions as targets and with wt p53 or Ala 143 mutant p53 as eectors. The mutant Ala 143 was used as a control eector since it had no eect on FGF ± CAT expression (Figure 2) . Western-blot analysis and RNase protection assays were carried out as described above. The VEGF ± CAT and the PDGF ± CAT proteins (45 and 27 kDa, respectively) were detected with the anti-CAT antisera and overexpression of p53 proteins was checked as above (Figure 3a) . Calibration of protein against RNA levels (Figure 3b ) did not reveal any underexpression of the CAT chimeric proteins when co-expressed with wt p53 as opposed to Ala 143 .
These results show that the post-transcriptional repressor eect of wt p53 is not generalized to mRNAs containing long leader sequences with IRES and is apparently, at least in these conditions, speci®c to FGF-2 mRNA.
The post-transcriptional inhibitory effect of p53 does not involve its trans-activator activity Three codons (Arg 175, Arg 248 and Arg 273) have been shown to be hotspots for mutation in human cancers (22% of all mutations reported so far). We therefore tested the eect of such mutants on the posttranscriptional expression of FGF ± CAT in SK-Hep-1 cells, as described for Figure 2 . We mutated Arg 175 into His or Leu, Arg 248 into Pro and Arg 273 into Pro and Leu. When compared with wt p53, all these tumour derived mutants were found to have lost the ability to repress FGF ± CAT expression, as had previously been observed with the Ala 143 mutation (Figure 4a ). The post-transcriptional expression of FGF ± CAT in SKHep-1 cells transfected with the Pro 248 , His 175 or Leu 273 mutants was even enhanced when compared to the control. However, this stimulatory eect did not seem to result from a dominant negative eect of these mutants on the endogenous wt p53 since it was also observed in p53-null Saos-2 cells (data not shown). (middle panel) and of p53 (lower panels) proteins was checked as described in Materials and methods. p53 was detected by using mouse monoclonal antibodies directed either against the amino-terminus of the protein (DO-1) or the carboxy-terminus (Pab421). The positions of the signals corresponding to FGF ± CAT isoforms and to p53 and p73 proteins are indicated by arrows. FGF ± CAT RNA and protein levels were determined for each transfection as described for Figure 2 It should be noted that the Leu 175 mutant retains some of the trans-activation properties of wt p53 when co-transfected with a reporter gene under the control of a promoter containing RGC sequences (data not shown) or of the p21 promoter (Ory et al., 1994) . This suggests that the activities of p53 on the posttranscriptional expression of FGF ± CAT and on the transcriptional trans-activation of target genes are independent. This hypothesis was further supported when the eector was either the p53-like protein, p73, or p21/waf, a major mediator of p53 anti-proliferative activity (el-Deiry et al., 1993) (Figures 4b and 5) . Indeed, neither p73a, which is expected to activate the expression of several p53 responsive genes (Jost et al., 1997; Kaghad et al., 1997) , nor p21/waf did exhibit any inhibitory eect when co-expressed with the FGF ± CAT RNA. (Figure 4b , lane 4 and Figure 5, lane 4) .
Finally, to determine whether the trans-activator activity of p53 was involved or not, we then studied the eect of a p53 trans-activator domain mutant, Gln 22 Ser 23 , in which leucine 22 and tryptophane 23 had been substituted by a glutamine and a serine, respectively. This double mutation results in a loss of the trans-activator properties of p53 (Haupt et al., 1995; Lin et al., 1994) . As the expression of this mutant could not be detected with the DO-1 monoclonal antibody directed against the aminoterminus of p53, we used the PAb-421 antibody directed against the carboxy-terminus of p53 (Figure 4b , bottom panel, lane 5). Clearly, the Gln 22 Ser 23 mutant is fully able to repress FGF ± CAT expression (upper panel, lane 5), thereby demonstrating that the repressor eect of wt p53 on the post-transcriptional expression of FGF ± CAT does not require its transactivator properties.
Discussion
In this study we demonstrate that p53 is able to repress FGF-2 expression post-transcriptionally, by a mechanism that does not involve its trans-activator domain. This new mode of action of p53 could be physiologically crucial in preventing the expression of abnormal FGF-2 isoforms in cells containing large amounts of FGF-2 mRNA, as observed in low density human skin ®broblasts.
The repression of FGF-2 translation appears to be speci®c to p53 since neither p73 nor p21, the major mediator of the anti-proliferative activity of p53 (elDeiry et al., 1993) , were able to reproduce this repressor eect (Figures 4 and 5) . These data also suggest that the repression of FGF-2 translation is not simply a non-speci®c consequence of growth inhibition induced by p53. This was investigated by examining the cell cycle of SK-Hep-1 cells transfected by bigenic vectors encoding p53 together with a cell surface antigen, by¯ow cytometry analysis. The resulting level of wt p53 expression obtained in the cells transfected with these vectors was not sucient to aect the cell cycle (data not shown).
The translational inhibitory eect of wt p53, observed in various transfected cells as well as in vitro, raised the question of the mode of action of p53. As this eect does not occur through mRNA destabilization, we propose that p53 is responsible for a direct or indirect translational inhibition, in concordance with the strongly decreased translatability of the endogenous FGF-2 mRNA observed in human skin ®broblasts (Figure 1) . Furthermore, in vitro translation assays performed with recombinant p53 show that the wt p53 is able to speci®cally inhibit translation initiation of Western blot analysis of FGF ± CAT (upper panel), p53 and p21 proteins expression (middle panels, with the corresponding signals indicated by arrows) and determination of the RNA levels were performed as in Figure 2 . The signals corresponding to FGF ± CAT isoforms were quanti®ed and calibrated against the FGF ± CAT RNA level as described for Figure 2 (histograms, 100% corresponds to cells transfected with the control eector) FGF ± CAT mRNA (Galy et al., submitted) . p53 could modulate the activity of factors involved in the control of FGF-2 mRNA translation such as the potential trans-acting proteins interacting with the FGF-2 mRNA leader (Vagner et al., 1996) . Alternatively, as p53 possesses strong RNA binding and annealing activities, it could act by direct interaction with the FGF-2 mRNA (Oberosler et al., 1993) . This interaction might block mRNA processing and/or nuclear export. Another attractive hypothesis is that p53 annealing activity would generate an RNA conformational change resulting in translation blockade. Data obtained from in vitro annealing experiments with recombinant p53 strongly argue in favour of such a mechanism (Galy et al., submitted) .
We describe here a trans-acting factor that is able to down-regulate FGF-2 mRNA translation: the fact that it is a tumour suppressor raises the important question of the physiological relevance of this p53 translational activity. In human skin ®broblasts, we have shown ( Figure 1 and Galy et al., 1999) that the FGF-2 mRNA is (relatively) abundant but very uneciently translated at low cell density. This suggests that p53, the expression of which is precisely increased in these conditions, might have the crucial role of maintaining an adequate level of FGF-2 in cells. Consequently, FGF-2 mRNA translation would no longer be regulated in transformed cells with mutated or inactivated p53: to support this hypothesis, we have observed that FGF-2 isoform expression is constitutive in several transformed cell lines, including human skin ®broblasts transformed by large T antigen, which is known to inactivate p53 (Galy et al., 1999) .
A recent report has shown that the FGF-2 IRES exhibits a tissue-speci®c activity in vivo (Creancier et al., 2000) . In particular, it is down-regulated in many organs of adult transgenic mice, whereas it is active in most cultured cells, the greatest activity being observed in the p53 7/7 Saos-2 cell line. The data presented here suggest that p53 might be one of the parameters responsible for this down-regulation of the FGF-2 IRES activity. However the absence of any eect of p53 on VEGF and PDGF IRESes activities, at least in cell cultures, suggests that p53 is not a general IRES inhibiting factor.
The role of FGF-2 in tumorigenesis has been largely documented (Bikfalvi et al., 1997) . FGF-2 promotes cancerous cell survival and proliferation, and tumour neovascularization. FGF-2 also acts as an anti-apoptotic factor (Fuks et al., 1994; Shaulian et al., 1997) . Conversely, p53 inhibits tumour angiogenesis and prevents accumulation of aberrant cells by inducing a large set of mechanisms leading to cell death (Bouck, 1996) . Therefore, we can hypothesize that p53, by inhibiting FGF-2 expression, would neutralize the antiapoptotic eect of FGF-2 and favour of the overbalancing of cells into apoptosis. Interestingly, it has been reported that the anti-apoptotic eect of FGF-2 can be due to the increased accumulation of mdm2 protein (Shaulian et al., 1997) . One can thus propose that in normal cells the equilibrium between FGF-2 and p53 is controlled by a negative regulatory loop in which wt p53 inhibits the translation of FGF-2, a factor able to induce mdm2, which in turn binds to and inactivates p53. As mutations of p53 occur in 50% of human cancers the disruption of such a regulatory loop may be determinant in tumour progression (Hollstein et al., 1991) .
Materials and methods
Plasmids construction
Bigenic vectors were derived from pcDNA 3 (Invitrogen) after multiple intermediate constructions that yielded to a plasmid containing the HincII/AatII (nt 3259 to 5445) + HincII/PvuII (nt 235 to 1289) + NruI/NdeI (nt 209 to 485) fragments from pCDNA3 + the NdeI/BglII fragment from pSCT12VCAT containing the FGF ± CAT fusion (Prats et al., 1992 ) + a poly(A) + site provided by oligonucleotides insertion (sense 5'-GATCTGCTTTCAATAAACTGCAAG-CAGACGT-3' and reverse 5'-CTGCTTGCAGTTTATT-GAAAGCA-3') at the AatII/BglII sites. Constructs containing the wild-type or mutant human p53 were created by insertion of the BamHI ± SmaI fragments from pc53-SN3 and pc53-SCX3 plasmids (Baker et al., 1990) into bigenic vectors (BamHI/EcoRV) containing the FGF ± CAT fusion. The deletion of the FGF-2 RNA leader (cf. Figure 2) was derived from these two plasmids. Mutagenesis of the p53 cDNA (His 175 , Leu 175 , Pro 248 , Pro 273 , Leu 273 and Gln 22 Ser 23 ) was performed by a sequential PCR step method. All the modi®ed cDNAs were veri®ed by sequencing. The CAT ORF fusion at the carboxy end of FGF-2 ORF (FC*) was extracted from the plasmid pSC50 (Bugler et al., 1991) . The PDGF ± CAT fusion was extracted from the plasmid pPD1 (Bernstein et al., 1997) and the VEGF ± CAT fusion from the plasmid pCVC0 (Huez et al., 1998) . CAT ORF was substituted into the FGF ± CAT fusion after ligation of the Xba/BglII fragment from the plasmid pSCTCAT (Prats et al., 1992) . The p73 a and p21/waf cDNAs (a gift from D Caput) was inserted into bigenic vectors after KpnI/SacI digestion.
Cell transfection and Western blot analysis
SK-Hep-1 and Saos-2 cells (no. ATCC: HTB 52 and HTB 85, respectively) were transfected in 60 mm petri dishes with 5 mg of plasmid by using the lipofectin reagent (Life Technologies). Cell lysates were prepared and analysed by Western immunobloting as previously described (Galy et al., 1999) . The rabbit anti-CAT polyclonal antibody was home made (1/ 5000 dilution). The mouse monoclonal antibodies were purchased from Santa-Cruz (DO-1 diluted to 1/10 000) or from Oncogene Science (Pab421 diluted to 1/1000). The rabbit anti-p73 was a gift from D Caput. The SC127 polyclonal anti-p21 antibody was from Santa-Cruz Inc (1/ 500 dilution). The immune complexes were detected by using an HRP coupled goat anti-rabbit or anti-mouse IgG antibody and an enhanced chemiluminescence kit (Amersham).
Preparation of cellular RNAs and RNase protection assay analysis
Total RNA was prepared by the RNAble method (Eurobio) according to the manufacturer's instructions and quanti®ed by UV absorbance at 260 nm.
The RNase protection assay was performed using the RPAII kit (Ambion) according to the manufacturer's instructions. Five mg of total RNA were incubated with an excess of a CAT antisense RNA probe labelled with a 32 P-CTP. The protected fragments were fractionated on a 5% polyacrylamide-urea gel. The gel was dried and used for signal quanti®cation in a phosphorimager system (Molecular Dynamics) with Image Quant software.
RNA quanti®cation by RT ± PCR was performed as described previously (Galy et al., 1999; Vagner et al., 1996) : brie¯y the cDNAs were synthesized using the Superscript TM pre-ampli®cation system from Life Technologies using 1 mg of total RNA, and 50 ng of random hexamers, in a ®nal volume of 20 ml. For FGF-2 mRNA quanti®cation, variable amounts of an internal standard RNA was added to the reactions (Vagner et al., 1996) . The PCR was performed with the 5' primer 5'-GCCACTTCAAGGA T / C CCCAAG-3' and the 3' primer 5'-TCAGCTCTTAGCAGACATTGG-3', hybridizing to regions 554 ± 573 and 931 ± 951 of FGF-2 cDNA, respectively. The 5' primer degeneration corresponds to a divergence between the human and bovine sequences. The PCR reactions were carried out using Goldstar Taq DNA polymerase (Eurogentec), in a ®nal volume of 50 ml, using variable amounts of cDNA (1 ml or less). The reaction was done on a TrioThermoblock apparatus (Eurogentec), in the following conditions: 948C 3 min, then 30 cycles of 948C 30 s/ 638C 1 min/ 728C 1 min, ®nally 728C 5 min. Ampli®ca-tion results (1/5 of the reactions) were analysed on 6% polyacrylamide gels (Tris Borate/EDTA), followed by ethidium bromide staining. The intensity of the ethidiumbromide luminescence was measured by image acquisition on a UV max apparatus (OSI) followed by an image treatment with NIH Image software, in conditions where the intensity of¯uorescence was linear (Vagner et al., 1996) . Abbreviations FGF, ®broblast growth factor; bFGF, basic ®broblast growth factor; IRES, internal ribosome entry site; TGFb1, transforming growth factor b1; VEGF, vascular endothelial growth factor; PDGF, platelet dierentiating growth factor; CAT, chloramphenicol acetyl-transferase; ORF, open reading frame; CMV, cytomegalovirus; RT ± PCR, reverse transcription and polymerase chain reaction; UTR, untranslated region.
